| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.14(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.88 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 8.9 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$0 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
3 |
3 |
| Total Shares Sold |
123,875 |
414,717 |
427,025 |
1,110,810 |
| Total Sell Value |
$798,994 |
$5,191,225 |
$5,313,647 |
$13,073,359 |
| Total People Sold |
4 |
6 |
6 |
9 |
| Total Sell Transactions |
4 |
10 |
13 |
48 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schulman Amy W |
Director |
– • – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
212 |
42,115 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2018-12-06 |
4 |
AS |
$12.46 |
$18,690 |
D/D |
(1,500) |
89,631 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2018-12-06 |
4 |
AS |
$12.47 |
$24,940 |
D/D |
(2,000) |
39,553 |
|
- |
|
| Consylman Gina |
Chief Financial Officer |
• – – |
2018-11-09 |
4 |
AS |
$11.81 |
$16,038 |
D/D |
(1,358) |
96,361 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-10-05 |
4 |
AS |
$17.53 |
$2,044,892 |
D/D |
(116,651) |
30,124 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-10-05 |
4 |
OE |
$10.24 |
$1,265,465 |
D/D |
116,651 |
146,775 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-10-04 |
4 |
AS |
$17.94 |
$2,110,678 |
D/D |
(116,650) |
30,124 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-10-04 |
4 |
OE |
$10.24 |
$1,265,454 |
D/D |
116,650 |
146,774 |
|
- |
|
| Schulman Amy W |
Director |
– • – |
2018-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
136 |
41,903 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2018-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
136 |
77,291 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2018-09-05 |
4 |
AS |
$19.10 |
$28,650 |
D/D |
(1,500) |
91,131 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2018-09-05 |
4 |
AS |
$19.10 |
$38,200 |
D/D |
(2,000) |
41,553 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-08-24 |
4 |
AS |
$18.39 |
$1,195,350 |
D/D |
(65,000) |
775,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-08-24 |
4 |
OE |
$4.89 |
$321,783 |
D/D |
65,000 |
840,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-08-23 |
4 |
AS |
$18.39 |
$1,195,350 |
D/D |
(65,000) |
775,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-08-23 |
4 |
OE |
$4.89 |
$321,784 |
D/D |
65,000 |
840,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-08-22 |
4 |
AS |
$18.51 |
$1,203,150 |
D/D |
(65,000) |
775,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-08-22 |
4 |
OE |
$4.89 |
$321,784 |
D/D |
65,000 |
840,000 |
|
- |
|
| Owens Edward P |
Director |
– • – |
2018-08-20 |
4 |
GA |
$0.00 |
$0 |
I/I |
40,000 |
40,000 |
|
- |
|
| Owens Edward P |
Director |
– • – |
2018-08-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
40,000 |
159,528 |
|
- |
|
| Consylman Gina |
Chief Financial Officer |
• – – |
2018-08-17 |
4 |
AS |
$18.21 |
$3,423 |
D/D |
(188) |
97,719 |
|
- |
|
| Mccourt Thomas A |
Chief Commercial Officer |
• – – |
2018-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
88,150 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2018-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
141,899 |
|
- |
|
| Consylman Gina |
Chief Financial Officer |
• – – |
2018-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
97,907 |
|
- |
|
| Huyett William |
Chief Operating Officer |
• – – |
2018-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
68,250 |
|
- |
|
584 Records found
|
|
Page 14 of 24 |
|
|
0.19 (2.99%) 
